| CAS ID: | 42794-76-3 |
| Molecular Formula: | C12H18N2O4 |
| Molecular Weight: | 254.3 g/mol |
| Monoisotopic Mass: | 254.1267 g/mol |
| Class: | Small Molecule |
| Natural Product: | No |
| Other Names: | ST. PETER 224 | ORVATEN | GUTRON | BRAMOX | PROAMATINE | MIDODRINE HYDROCHLORIDE | Midodrine | A-4020 LINZ | ST-1085 | MIDON | ST 1085 [AS THE BASE] |
| Analysis: | Drug repositioning mechanism analysis |
Trial Record 1
| ClinicalTrial ID | NCT01587222 | Disease | Renal fibrosis |
| Phase | Phase 2 | Status | Withdrawn |
| First Received | April 30, 2012 | Last Verified | February 15, 2019 |
| Sponsor | Anna Cruceta | ||
Trial Record 2
| ClinicalTrial ID | NCT03144713 | Disease | Liver fibrosis |
| Phase | Not Applicable | Status | Completed |
| First Received | May 9, 2017 | Last Verified | September 5, 2018 |
| Sponsor | Institute of Liver and Biliary Sciences, India | ||
Trial Record 3
| ClinicalTrial ID | NCT02173288 | Disease | Liver fibrosis |
| Phase | Phase 2,Phase 3 | Status | Completed |
| First Received | June 24, 2014 | Last Verified | September 19, 2017 |
| Sponsor | Postgraduate Institute of Medical Education and Research | ||
Trial Record 4
| ClinicalTrial ID | NCT01133795 | Disease | Liver fibrosis |
| Phase | Phase 2 | Status | Completed |
| First Received | May 31, 2010 | Last Verified | August 18, 2016 |
| Sponsor | Hospital Clinic of Barcelona | ||
Trial Record 5
| ClinicalTrial ID | NCT00108355 | Disease | Liver fibrosis |
| Phase | Phase 4 | Status | Completed |
| First Received | April 15, 2005 | Last Verified | March 6, 2014 |
| Sponsor | US Department of Veterans Affairs | ||
Trial Record 6
| ClinicalTrial ID | NCT00742339 | Disease | Liver fibrosis |
| Phase | Phase 2,Phase 3 | Status | Terminated |
| First Received | August 27, 2008 | Last Verified | October 15, 2014 |
| Sponsor | University of Padova | ||
| PubChem: | 4195 |
| ChEMBL: | CHEMBL1201212 |